Serum FGF21 and RBP4 levels in patients with chronic hepatitis C

Kukla, Michał; Berdowska, Agnieszka; Stygar, Dominika; Gabriel, Andrzej; Mazur, Włodzimierz; Logiewa-Bazger, Beata; Sobala-Szczygieł, Barbara; Bułdak, Rafał Jakub; Rokitka, Maria; Zajęcki, Wojciech; L, Kepa; Sawczyn, Tomasz; Żwirska-Korczala, K

doi:10.3109/00365521.2012.694901

Cited by 19 publications

(19 citation statements)

References 43 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In HCV infected patients, studies showed that both mRNA levels of PPAR-a and FGF21 were downregulated with a concomitant elevation in the level of HCV RNA [13]. However, in another cross-sectional study, serum FGF21 level suggested a positive correlation with steatosis grade in chronic hepatitis C patients [66]. Given FGF21 elevation in the subjects with hepatic steatosis could induce several liver diseases aforementioned, it is possible that FGF21 is increased in HCV.…”

Section: Fgf21 In Viral Hepatitismentioning

confidence: 95%

See 1 more Smart Citation

The role of fibroblast growth factor 21 in the pathogenesis of liver disease: a novel predictor and therapeutic target

Liu

Huang

Shi

et al. 2014

Expert Opinion on Therapeutic Targets

View full text Add to dashboard Cite

show abstract

Section: Fgf21 In Viral Hepatitismentioning

confidence: 95%

“…HCV infection may correlate with FGF21 expression [13,66]. In HCV infected patients, studies showed that both mRNA levels of PPAR-a and FGF21 were downregulated with a concomitant elevation in the level of HCV RNA [13].…”

Section: Fgf21 In Viral Hepatitismentioning

confidence: 99%

The role of fibroblast growth factor 21 in the pathogenesis of liver disease: a novel predictor and therapeutic target

Liu

Huang

Shi

et al. 2014

Expert Opinion on Therapeutic Targets

View full text Add to dashboard Cite

show abstract

“…However, another study by Kukla et al . did not confirm these observations in CHC [92]. Further investigations involving a larger number of patients are required to better determine the exact role of novel adipokines in CHC.…”

Section: Molecular Mechanisms Of Hcv-induced Insulin Resistancementioning

confidence: 99%

Review article Insulin resistance and its consequences in chronic hepatitis C

Kukla¹,

Piotrowski²,

Waluga³

et al. 2015

ceh

Self Cite

View full text Add to dashboard Cite

Chronic hepatitis C (CHC) is generally a slowly progressive disease, but some factors associated with rapid progression have been identified. Hepatitis C virus (HCV) may contribute to a broad spectrum of metabolic disturbances – namely, steatosis, insulin resistance (IR), increased prevalence of impaired glucose tolerance, type 2 diabetes mellitus (T2DM), lipid metabolism abnormalities and atherosclerosis.HCV can directly or indirectly cause both IR and steatosis, but it is still not resolved whether this viral impact bears the same prognostic value as the metabolic counterparts. As the population exposed to HCV ages, the morbidity due to this disease is increasing. The rising epidemic of obesity contributes to higher prevalence of IR and T2DM. Our understanding of the mutual association between both disease states continues to grow, but is still far from complete. This review briefly discusses the most probable mechanisms involved in IR development in the course of CHC. Molecular mechanisms for the direct and indirect influence of HCV on intracellular insulin signaling are described. Subsequently, the consequences of IR/T2DM for disease progression and management are summarized.

show abstract

“…Moreover, IR is a strong predictor of poor response to antiviral therapy, alongside advanced hepatic steatosis and fibrosis [6,14]. Numerous reports have demonstrated altered levels of some adipokines such as leptin, adiponectin, resistin, visfatin, vaspin, chemerin and fibroblast growth factor (FGF) 21 in CHC patients [4,15,16,17,18,19,20].…”

Section: Introductionmentioning

confidence: 99%

Omentin serum concentration and hepatic expression in chronic hepatitis C patients – together or apart?

Kukla¹,

Waluga²,

Adamek³

et al. 2015

pjp

Self Cite

View full text Add to dashboard Cite

Chronic hepatitis C (CHC) is accompanied by numerous metabolic disorders, partially associated with altered adipokine system regulation. Omentin (intelectin-1) is a novel adipokine known to play a pivotal role in metabolic regulation in CHC. In a group of 63 CHC patients (29 men/34 women) infected with genotype 1b, aged 6.6 ±14.6 years, serum omentin levels and its gene expression in liver tissue were examined and their association with metabolic and histopathological features was assessed. Serum omentin levels were significantly higher in CHC patients compared to controls (p < 0.001), regardless of sex, body mass index (BMI), insulin sensitivity and lipid concentrations. There was no correlation between serum omentin and omentin hepatic expression. Neither parameter was associated with any histological features. Serum omentin in non-obese CHC patients seems not to be related to metabolic disorders or liver pathology. Omentin hepatic expression shows no relationship with either serum omentin levels or histopathological features. This suggests different mechanisms regulating circulating omentin concentration and omentin hepatic expression in CHC.

show abstract

Serum FGF21 and RBP4 levels in patients with chronic hepatitis C

Cited by 19 publications

References 43 publications

The role of fibroblast growth factor 21 in the pathogenesis of liver disease: a novel predictor and therapeutic target

The role of fibroblast growth factor 21 in the pathogenesis of liver disease: a novel predictor and therapeutic target

Review article Insulin resistance and its consequences in chronic hepatitis C

Omentin serum concentration and hepatic expression in chronic hepatitis C patients – together or apart?

Contact Info

Product

Resources

About